


























































published: 08 August 2014
doi: 10.3389/fncel.2014.00225
High-fat-diet-induced weight gain ameliorates bone loss
without exacerbating AβPP processing and cognition in
female APP/PS1 mice
Yunhua Peng1, Jing Liu1,YingTang1, Jianshu Liu2,Tingting Han2, Shujun Han1, Hua Li 1, Chen Hou1,
Jiankang Liu1 and Jiangang Long1*
1 Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and
Technology and Frontier Institute of Science and Technology, Xi’an Jiaotong University, Xi’an, China
2 Shaanxi Translational Center for Functional Foods, Xi’an, China
Edited by:
Rena Li, Roskamp Institute, USA
Reviewed by:
Nicolas Blondeau, Centre National de
la Recherche Scientifique, France
Jie Cui, Roskamp Institute, USA
*Correspondence:
Jiangang Long, Center for
Mitochondrial Biology and Medicine,
School of Life Science and
Technology, Xi’an Jiaotong University,
No. 28, Xianning West Road, Xi’an,
Shaanxi 710049, China
e-mail: jglong@mail.xjtu.edu.cn
Osteoporosis is negatively correlated with body mass, whereas both osteoporosis and
weight loss occur at higher incidence during the progression of Alzheimer’s disease (AD)
than the age-matched non-dementia individuals. Given that there is no evidence that being
overweight is associated with AD-type cognitive dysfunction, we hypothesized that moder-
ate weight gain might have a protective effect on the bone loss in AD without exacerbating
cognitive dysfunction. In this study, feeding a high-fat diet (HFD, 45% calorie from fat) to
female APP/PS1 transgenic mice, an AD animal model, induced weight gain. The bone
mineral density, microarchitecture, and biomechanical properties of the femurs were then
evaluated. The results showed that the middle-aged female APP/PS1 transgenic mice
were susceptible to osteoporosis of the femoral bones and that weight gain significantly
enhanced bone mass and mechanical properties. Notably, HFD was not detrimental to
brain insulin signaling and AβPP processing, as well as to exploration ability and working,
learning, and memory performance of the transgenic mice measured by T maze and Mor-
ris water maze, compared with the mice fed a normal-fat diet (10% calorie from fat). In
addition, the circulating levels of leptin but not estradiol were remarkably elevated in HFD-
treated mice. These results suggest that a body weight gain induced by the HFD feeding
regimen significantly improved bone mass in female APP/PS1 mice with no detriments
to exploration ability and spatial memory, most likely via the action of elevated circulating
leptin.
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INTRODUCTION
Alzheimer’s disease (AD), the most common type of dementia,
is defined as “the disease or injury which initiated the train of
events leading directly to death” by World Health Organization
(Alzheimer’s Association, 2014). Growing incidence rate of AD
worldwide makes it emergent to deal with its complications, such
as osteoporosis (Bredesen and John, 2013). Some studies have indi-
cated that low bone mineral density (BMD) or an increased rate
of BMD loss is associated with a higher risk of AD (Tan et al.,
2005; Zhou et al., 2011). Epidemiology studies also show that AD
itself is an independent risk factor for bone impairment (Sato
et al., 1998; Weller and Schatzker, 2004; Loskutova et al., 2009),
particularly in postmenopausal females (Andersen et al., 1999;
Yoshimura et al., 2005). More importantly, in patient with AD, the
progression of osteoporosis is correlated with the AD pathogenesis
(Lee et al., 2012).
It is evidenced that low body mass index (BMI) is associated
with osteoporosis (Felson et al., 1993; Tremollieres et al., 1993;
Ravn et al., 1999; De Laet et al., 2005), while obese individuals
generally exhibit high BMD and bone strength (Reid et al., 1992;
Khosla et al., 1996; Reid, 2002; Andersen et al., 2014; Johansson
et al., 2014). Patients with AD exhibit a significant weight loss
compared to the age-matched normal controls (White et al., 1996,
1998; Cronin-Stubbs et al., 1997; Stewart et al., 2005). There is no
debate that being severely obese (BMI> 40) increases the risk for
many illnesses and even increases mortality. However, the mod-
erate overweight (25<BMI< 30) showed a protective effect of
lowering the mortality (Flegal et al., 2013; Couzin-Frankel, 2014;
Solon-Biet et al., 2014), and some evidences suggest that being
overweight is not associated with AD-type cognitive dysfunction
(Kalmijn et al., 2000; Kivipelto et al., 2005). Thus, we hypothesized
that moderate weight gain may improve the bone loss without
exacerbating cognitive dysfunction in AD.
As one approach leading to weight gain, an extremely high-fat
diet (HFD, 60% calorie from fat) was previously shown to induce
a remarkable brain insulin resistance as well as spatial memory
impairment in a normal mouse or a transgenic mouse model of
AD (Ho et al., 2004; Moroz et al., 2008; Leboucher et al., 2013).
In contrast, a moderate HFD (45% calorie from fat) caused lit-
tle impairment in central insulin signaling and spatial memory
(Mielke et al., 2006; McNeilly et al., 2012), although an oper-
ant bar-pressing task appeared to be capable of distinguishing
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the mice fed a moderate HFD from the vehicle controls (Mielke
et al., 2006; McNeilly et al., 2011). Therefore, in this study, we
induced a body weight gain in female APP/PS1 transgenic mice
by feeding a moderate HFD (45% calorie from fat) to investigate
the bone remodeling and the cognitive function. We found that
severe femoral bone loss occurred in this transgenic mouse model
of AD, and the body weight gain induced by the HFD greatly
improved bone mass and mechanic properties. However, cerebral
insulin signaling, AβPP processing, exploration ability, and spatial
learning and memory were not deteriorated in transgenic mice fed
HFD compared with the transgenic mice fed the control diet (10%
calorie from fat). Our results suggested that the body weight man-
agement deserves to be evaluated in individuals with AD, especially
those who experience progressive weight loss and osteoporosis.
MATERIALS AND METHODS
ANIMALS
The APPswe/PS1dE9 (APP/PS1) transgenic mice express both
human presenilin 1 (A246E variant) and a chimeric amyloid pre-
cursor protein (APPswe) under direction of the mouse prion
protein promoter, and on the C57BL/6J background (Borchelt
et al., 1997). Three-month-old APP/PS1 female transgenic mice
and non-transgenic littermates (C57BL/6 mice) were used for
this study. The mice were purchased from Nanjing Biomed-
ical Research Institute of Nanjing University (Nanjing, Jiangsu,
China) and housed at 23–25°C with 60% humidity under 12:12 h
light:dark cycles, with free access to food and water throughout
the experiment. The mice were divided into three groups: wild-
type mice (C57BL/6 group, n= 10), APP/PS1 transgenic mice
(APP/PS1 group, n= 12), and APP/PS1 transgenic mice fed the
HFD (APP/PS1+HFD group, n= 11). During the 6 months of
feeding, the mice consumed ad libitum either a control purified
diet (10% calorie from fat) for the C57BL/6 group and APP/PS1
group, or an HFD (45% calorie from fat) for APP/PS1+HFD
group. The composition of each diet and the fatty acid profile of
each diet are listed in Table S1 in Supplementary Material. The
detailed formula of each fat diet is given in Table S2 in Supple-
mentary Material. The body weights were recorded weekly. All the
experimental procedures followed the Guide for the Care and Use
of Laboratory Animals: Eighth Edition, ISBN-10:0-309-15396-
4, and the animal protocol was approved by the animal ethics
committee of School of Life Science, Xi’an Jiaotong University.
At 8.5 months of age, the mice were subjected to a T-shaped
maze on 1 day. Three days later, the mice were subjected to a water
maze every day for 7 days. The mice were sacrificed by decapi-
tation 3 days after the end of the water maze testing, so that the
age of mice when they were sacrificed was 9 months. The brain,
liver, and serum were harvested, as well as the femurs in both
hindlimbs. The left femur was stored in saline at 4°C for the mea-
surement of mechanical parameters. The right femur was fixed in
10% formaldehyde for micro-CT scanning.
MEASUREMENTS OF EXPLORATION ABILITY, WORKING, LEARNING
AND MEMORY PERFORMANCE WITH THE T-MAZE ANDWATER MAZE
The T-shaped maze was constructed with one start arm and two
goal arms, all with a length of 30 cm, width of 10 cm, and height
of 20 cm. Spontaneous alternation of the T-maze is based on the
assumption that the mouse always prefers to explore the new arm
rather than the familiar arm (Gerlai, 1998). The tested mouse was
first placed in the start arm of the T-maze. The mouse was then
free to choose to enter either the left or the right goal arm (Reisel
et al., 2002; Deacon and Rawlins, 2005). The choices of each mouse
were recorded to calculate the percentage of alternations for eight
trials with a 15-min interval between each trail. The latency time
to reach the goal arm for each mouse was also recorded.
The Morris water maze tests were conducted in a diameter of
120 cm round tank filled with opaque water. The water was kept at
25°C and surrounded by dark walls containing geometric designs
as visual cues. The hidden 7.5 diameter platform was submerged
0.5 cm below the water surface. The day before the first testing
day, each mouse was allowed to swim freely in the tank for 90 s.
On the first day of the training, each mouse was placed in two
different quadrants of the pool and was required to find the hid-
den platform for two trials with a maximum of 120 s for each
trial. For the next 5 days, each mouse was placed in three differ-
ent quadrants of the pool and allowed a maximum of 120 s to
find the submerged platform. During the consecutive 6 days of
training, if the mice failed to find the platform within 120 s, they
were physically guided to it and allowed to remain on the plat-
form for 20 s. On the seventh day that after 6 days of training, the
platform was removed and mice were tested with a probe trial.
The total time for each mouse was 45 s. The performance in all
tasks (escape latency to platform and distance to target quadrant
during training phase; mean crossings on platform during probe
trial) was recorded using a computer-based video tracking system
(Vorhees and Williams, 2006).
MEASUREMENT OF BRAIN Aβ
The cortex was dissected and homogenized in ice-cold guanidine
buffer (5 M guanidine HCl/50 mM Tris HCl, pH 8.0) containing
protease inhibitor mixture (5 mM sodium pyrophosphate, 1 mM
β-glycerolphosphate, 1 mM Na3VO4, 1 mM EDTA, and 1µg/ml
leupetin). The amounts of soluble Aβ40 and Aβ42 in brain cortical
homogenates were determined by ELISA kits for Aβ40 and Aβ42
(Invitrogen, Camarillo, CA, USA), respectively, according to the
manufacturer’s instructions. In brief, 50µl standards of known
human Aβ40 or Aβ42 and the tested samples were added to the
wells pre-coated with NH2-terminus of human Aβ. Then, 50µl
human Aβ40 or Aβ42 detection antibody solution was added into
each well. The standards and samples were detected with horse-
radish peroxidase (HRP)-labeled anti-rabbit antibodies for the
COOH-terminus of the 1–40 Aβ or 1–42 Aβ sequence. The reac-
tions were stopped by adding 100µl stop solution. The optical
density (OD) at a wavelength of 450 nm was measured by FlexS-
tation 3 microplate reader (Molecular Devices, Sunnyvale, CA,
USA). The protein concentrations of the homogenates were deter-
mined using the BCA method, and Aβ40 and Aβ42 were expressed
as pg Aβ40 or Aβ42/mg protein.
WESTERN BLOT
The brain samples were lysed with Western and IP lysis buffer
(Beyotime, Haimen, Jiangsu, China) and centrifuged at 13,000 g
for 15 min. The protein concentrations were determined using
the BCA protein assay kit, and equal amounts of each protein
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(10µg) were subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE), transferred to pure nitrocellulose
membranes (PerkinElmer Life Sciences, Boston, MA, USA), and
blocked with 5% non-fat milk in Tris-buffered saline Tween-
20 (TBST) buffer. The membranes were incubated with pri-
mary antibodies (diluted by 1:1,000 to 1:10,000) for 3 h at
room temperature. The antibodies against AβPP, AKT, p-AKT,
GSK3β, and p-GSK3β were purchased from Cell Signaling Tech-
nology (Danvers, MA, USA), the Aβ antibody anti-6E10 was
from Covance (Dedham, MA, USA), and the antibody against
actin was from Invitrogen (Carlsbad, CA, USA). The mem-
branes were subsequently incubated with anti-rabbit or anti-
mouse antibodies for 1 h at room temperature. Chemiluminescent
detection was performed using the Pierce ECL Western blot-
ting substrate, and the signals were analyzed using Quantity One
software.
FEMUR MECHANICAL PROPERTY TESTING
The mechanical properties of the femurs were determined using a
three-point bending test that fractured the middle of the femoral
region. The round-surfaced cross-head probe of a servo-controlled
electromechanical testing system (Instron 5567, Canton, MA,
USA) contacted the medial femur surface at its longitudinal mid-
point within a 10 mm loading span. Loading speed was applied
at 1 mm/min, and the load–deformation curve was recorded for
calculation of elastic stress, elastic modulus, elastic force and ulti-
mate force to fracture, energy absorption, and stiffness. The femur
length was measured using digital calipers. The maximum and
minimum outer and inner diameters of the fractured section were
also measured using digital calipers for calculation of the second
moment of inertia. The elastic force was the maximum load of the
elastic (linear) region of the load–deformation curve. The ulti-
mate force was the maximum load when the fracture occurred,
which is defined as the height of the curve. Energy absorption was
calculated as the product of load and displacement, defined as the
area under the elastic region of the curve. Stiffness was calculated
as the slope of the elastic region of the curve. The second moment
of inertia (J ), elastic stress (σϕ), and elastic modulus (E) were
calculated according to the formulas below (Jämsä et al., 1998;






σϕ = Fp −H × L
8× J
E = Fp − L
3
48× dp × J
where Fp is the difference between the highest and lowest loads of
the elastic part of the load–displacement curve; dp is the difference
between the maximum and minimum displacements of the elastic
part of the load–displacement curve; L is the span length between
two support points (10 mm); and H, h, B, and b are the maxi-
mum outer diameter, minimum outer diameter, maximum inner
diameter, and minimum inner diameter of the fracture section,
respectively.
MICRO-CT SCANNING
To determine the BMD and microarchitecture, the right femur
was scanned using a micro-CT scanner (GE eXplore Locus SP
Micro-CT, GE Healthcare, Barrington, IL, USA). All scans were
performed with 80 kV tube voltage and 80µA tube current and an
exposure time of 3000 ms. The voxel size was 8.0µm× 8.0µm×
8.0µm for the trabecule analysis, and the angle of the increment
was set to 0.5°. A fixed threshold was used to extract the mineral-
ized bone phase by averaging the critical value of the grayscale. The
region of interest (ROI) was the entire volume inside the femur
head. The trabecular volumetric BMD (vBMD), representing the
apparent BMD of the trabecule at the organ level, was calculated
from all voxels in the ROI. The trabecular tissue BMD (tBMD),
representing the BMD at the tissue level, was defined as the tis-
sue mineral content divided by the volume of the fixed threshold
voxels.
Other data were also calculated from the ROI, including bone
volume fraction (BV/TV), trabecular number (Tb.N), trabecu-
lar thickness (Tb.Th), and trabecular separation (Tb.Sp). For
the cortical bone, the data were taken from a 2-mm-long round
region of the mid-diaphysis femur and included the mean thick-
ness (Ct.Th), bone mineral content (BMC) and density (BMD),
total area (Tt.Ar), cortical area (Ct.Ar), marrow area (Ma.Ar), and
cortical area fraction (Ct.Ar/Tt.Ar) (Bouxsein et al., 2010).
All the micro-CT data were calculated using MicroView v2.1.1
software and Advanced Bone Analysis application (GE Healthcare,
Barrington, IL, USA).
BIOCHEMICAL ASSAYS OF SERUMMARKERS
The blood samples were allowed to clot undisturbed for 30 min
at room temperature. The sera were separated from the blood
samples by centrifugation at 1,500 rpm for 15 min. The serum
total cholesterol (mmol/L), triglycerides (mmol/L), alkaline phos-
phatase (ALP, IU/L), calcium (Ca2+, mmol/L), and phosphorus
(P, mmol/L) were measured using an automated HITACHI 7600
clinical analyzer (HITACHI, Ltd., Tokyo, Japan).
The serum estradiol levels were measured using a mouse estra-
diol (E2) ELISA Assay Kit according to the manual (Nanjing
Jiancheng Bioengineering Institute, Nanjing, China). Briefly, 40µl
samples, 10µl biotin-labeled mouse E2 antibodies, and 50µl
HRP-conjugated streptavidin were combined in this order in the
assay plate wells, which were pre-coated with mouse E2 mono-
clonal antibody. After incubation for 60 min at 37°C, the plate was
washed five times to remove the uncombined enzyme, and the
substrate components A (50µl) and B (50µl) were added to the
well. After approximately 15 min of reaction time, the reaction was
stopped by adding 50µl of the stop solution. The OD at 450 nm
was measured using a FlexStation 3 microplate reader.
The serum leptin levels were measured using a mouse leptin
ELISA kit (Crystal Chem, Downers Grove, IL, USA) according to
the manufacturer’s instructions. Briefly, 45µl of the sample dilu-
ent, 50µl anti-mouse leptin serum, and 5µl sample were added in
this order to the assay plate wells, which were pre-coated with
mouse leptin antibody. After incubation overnight at 4°C, the
plate was washed five times to remove the uncombined enzyme,
and 100µl substrate was added to each well. After approximately
30 min at room temperature, the reaction was stopped by adding

























































Peng et al. High-fat-diet ameliorates AD bone loss
100µl stop solution. The ODs at 450 and 630 nm were measured
using a FlexStation 3 microplate reader.
STATISTICAL ANALYSIS
Ten C57BL/6 mice, 12 APP/PS1 mice, and 11 APP/PS1+HFD
mice were fed since 3 months old. Thus, for the measurements of
body weight, spatial learning and memory, and mechanical prop-
erties, the sample size was 10 for C57BL/6 mice, 12 for APP/PS1
mice, and 11 for APP/PS1+HFD mice. When the mice were sac-
rificed, 3 mice from each group were randomly selected to perfuse
paraformaldehyde for immunohistochemistry experiments (data
not shown in the text). For ELISA and western blot, the sample
size is 7 for C57BL/6 mice, 9 for APP/PS1 mice, and eight for
APP/PS1+HFD mice. Due to the fact that a femur in APP/PS1
group was damaged and excluded from samples, 7 of C57BL/6
mice, 8 of APP/PS1 mice, and 8 of APP/PS1+HFD mice were
used for the micro-CT scanning.
All data were expressed as the means± SEM. One-way analy-
sis of variance (ANOVA) with a Newman–Keuls post hoc test
or two-way ANOVA with a Bonferroni’s post hoc test was used
to determine the differences among the groups. Significance was
defined at the 0.05 level.
RESULTS
BODY WEIGHT, PERIMETRIC FAT WEIGHT, AND LEVELS OF SERUM
CHOLESTEROL AND TRIGLYCERIDE
During the feeding period, the initial body weights of the mice
were 21.66± 1.29 g, and the final body weights of APP/PS1+HFD
mice (46.00± 9.72 g) were approximately 77.2 and 68.8% greater
than those of C57BL/6 (25.96± 1.29 g) and APP/PS1 mice
(27.25± 1.45 g), respectively, whereas no difference was found
between the body weights of the C57BL/6 mice and APP/PS1
groups (Figure 1A). The ratio of the perimetric fat pad weight to
body weight was 1.7 and 1.0 times higher in the APP/PS1+HFD
mice than those of the C57BL/6 and APP/PS1 mice, respec-
tively (Figure 1B). A higher level of serum cholesterol was
observed in the transgenic mice that were fed the HFD, while
levels of serum triglycerides were not different among all groups
(Figures 1C,D).
EXPLORATION ABILITY AND SPATIAL LEARNING AND MEMORY
MEASURED BY T-MAZE ANDWATER MAZE
To evaluate whether the HFD accelerated the development of
AD, the behavioral tests (T-maze and water maze) were con-
ducted in the 9-month-old animals. The APP/PS1 group and
APP/PS1+HFD group exhibited impaired exploration ability,
spatial learning and memory abilities, as indicated by fewer
alternative choices and longer latency in the T-maze test, and
longer escape latency and distance during training phase, and
fewer crossings on the platform during probe trial in the water
maze test compared to the C57BL/6 mice. Notably, no signifi-
cant behavioral differences were found between the APP/PS1 and
APP/PS1+HFD groups (Figures 2A–E) in this study, suggesting
that feeding a diet at a level of 45% calorie from fat for as long as
6 months does not lead to a detriment of exploration ability, spa-
tial learning and memory in the female transgenic mouse model
of AD.
FIGURE 1 | High-fat-diet-induced weight gain in APP/PS1 mice.
Throughout the experiment, the body weights of C57BL/6 and APP/PS1
mice had no difference, and significant body weight gain was induced after
HFD feeding for 8 weeks (at 22 weeks) and sustained growing from then
on (A). The ratio of parametric fat pad weight to body weight (B) of APP/
PS1+HFD mice was significantly higher than that of the C57BL/6 and
APP/PS1 mice. The serum level of total cholesterol in APP/PS1+HFD mice
was higher than those in the other two mice groups (C). No difference in
serum triglycerides was found among the three groups (D). Data were
means±SEM. n=10 for C57BL/6 mice, n=12 for APP/PS1 mice, and
n=11 for APP/PS1+HFD mice for body weight. n=7 for C57BL/6 mice,
n=9 for APP/PS1 mice, and n=8 for APP/PS1+HFD mice for other
measurements. All results were analyzed by one-way ANOVA, followed by
Newman–Keuls post hoc test, except that the body weight result was
analyzed by two-way ANOVA, followed by Bonferroni’s post hoc test.
***p<0.001.
BRAIN INSULIN SIGNALING AND AβPP PROCESSING
Neuronal insulin resistance has been confirmed in the brain of AD
(Talbot et al., 2012). The neuronal insulin acts through a sim-
ilar tyrosine kinase pathway as peripheral insulin acts. Insulin
binds to insulin receptor (IR) followed by phosphorylation of
phosphatidylinositol 3-kinase (PI3K), which leads to AKT/protein
kinase B (PKB) phosphorylation and activation, and then glyco-
gen synthesis kinase 3 (GSK3) is phosphorylated and inactivated
(El Khoury et al., 2014). HFD feeding is linked to cognitive impair-
ment mediated by brain insulin resistance and accelerated Aβ
generation (Ho et al., 2004; McNeilly et al., 2011). The neural levels
of p-AKT and p-GSK3 were determined in this study to evaluate
the brain insulin signaling. The Aβ levels were also measured in
APP/PS1 mice fed HFD (Figures 3A–I).
In C57BL/6 mice, soluble Aβ40 and Aβ42 levels measured by
ELISA, and Aβ precursor protein (AβPP), Aβ tetramer, and Aβ
dimer levels assessed by western blots turned out to be very low
or zero, whereas APP/PS1 and APP/PS1+HFD mice had much
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FIGURE 2 | HFD did not deteriorate the working, learning and
memory performance in APP/PS1 mice. In the T-maze spontaneous
alternation test, both APP/PS1 group and APP/PS1+HFD group showed
fewer percentages to make the alternative choices (A) and had a longer
latency time (B) than C57BL/6 group. APP/PS1 group exhibited significant
longer escape latency on days 3, 5, and 6, and longer distance on days 2,
3, 4, and 5, while APP/PS1+HFD group exhibited significant longer
escape latency on days 3, and 6, and longer distance on days 2 and 3
(C,D). The mean crossings of the C57BL/6 group were more frequent than
those of APP/PS1 and APP/PS1+HFD groups (E). Additionally, no
difference was found between the APP/PS1 and APP/PS1+HFD groups.
Data were means±SEM. n=10 for C57BL/6 mice, n=12 for APP/PS1
mice, and n=11 for APP/PS1+HFD mice. T-maze results were analyzed
by one-way ANOVA, followed by Newman–Keuls post hoc test. *p<0.05;
**p<0.01. The water maze result was analyzed by two-way ANOVA,
followed by Bonferroni’s post hoc test. ∧p<0.05; ∧∧p<0.01; ∧∧∧p<0.001,
APP/PS1 versus C57BL/6; #p<0.05; ##p<0.01; ###p<0.001, APP/PS1+
HFD versus C57BL/6.
higher levels of those parameters (Figures 3A–F). Importantly,
the Aβ40, Aβ42, AβPP, Aβ tetramer, and Aβ dimer levels were com-
parable in the APP/PS1+HFD mice and the APP/PS1 mice fed
the normal-fat diet (Figures 3A–F). Consistent with these obser-
vations, the APP/PS1 and APP/PS1+HFD mice showed elevated
levels of AKT phosphorylation compared to the C57BL/6 mice, but
no significant differences between APP/PS1 and APP/PS1+HFD
mice were observed (Figures 3G,H). The p-GSK3β expression
was even higher in APP/PS1+HFD mice than in APP/PS1 and
C57BL/6 mice (Figures 3G,I). These results suggested that HFD
did not aggravate Aβ generation and brain insulin signaling
impairment in the female transgenic mice.
MECHANICAL PARAMETERS OF THE FEMORAL BONE
To understand the mechanical effects of AD pathology and HFD-
induced body weight gain on bone, we employed the three-point
bending test to measure the mechanical properties of the femurs
(Figures 4A–H). We found that the elastic force and ultimate force
were both significantly reduced in APP/PS1 mice compared to the
age-matched C57BL/6 mice and that these effects were completely
reversed by the HFD (Figures 4A,B). With respect to the second
moment of inertia, which reflects the geometric size of bone, and
load-displacement curve, we found that elastic stress and energy
absorption decreased in the APP/PS1 mice and were reversed by
the HFD (Figures 4C–E). Although no differences in the elastic
modulus and stiffness were observed between the C57BL/6 and
APP/PS1 mice, HFD significantly increased the values of these
two parameters (Figures 4F,G). Ultimate stress was not different
among the three groups of mice (Figure 4H). The femur length
was shorter in APP/PS1 mice compared to C57BL/6 mice, and this
effect was not altered by the HFD (Figure 4I).
BONE MINERAL DENSITY AND MICROARCHITECTURAL PARAMETERS
OF THE FEMORAL BONE
To determine the structural basis for the alteration in biomechan-
ical properties, we further evaluated the cortical bone in femurs
using a micro-CT system. Compared to the C57BL/6 group, the
APP/PS1 group had lower values for BMD, BMC, and mean thick-
ness (Ct.Th) of cortical femur but showed no significant decreases
in total area (Tt.Ar) and cortical area (Ct.Ar) (Figures 5A–E,H).
Ct.Ar/Tt.Ar was decreased in the APP/PS1 mice (Figure 5G) com-
pared with the C57BL/6 mice. HFD feeding resulted in significant
increases in BMD, BMC, Ct.Th, Tt.Ar, and Ct.Ar of the mea-
sured bone in APP/PS1 mice (Figures 5A–E,H). There were no
significant differences in marrow area (Ma.Ar) among the groups
(Figure 5F). The micrographs also revealed that the inner bone
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FIGURE 3 | Soluble Aβ level and brain insulin signaling. Aβ40 (A), and
Aβ42 (B) levels were much higher in APP/PS1 and APP/PS1+HFD mice
compared with that those of C57BL/6 mice, and the Aβ40 and Aβ42 levels
were determined to be the same between APP/PS1 and APP/PS1+
HFD mice by ELISA. The expression of AβPP, Aβ tetramer, Aβ dimer (C),
phosphorylation of AKT, and phosphorylation of GSK3β (G) in brain
tissue were analyzed by western blot. Quantification of western blot of
AβPP (D), Aβ tetramer (E), Aβ dimer (F), p-AKT (H), and p-GSK3β (I).
Data were means±SEM. n=7 for C57BL/6 mice, n=9 for APP/PS1
mice, and n=8 for APP/PS1+HFD mice. The results were analyzed by
one-way ANOVA, followed by Newman–Keuls post hoc test.
***p<0.001.
surface facing the marrow was much smoother in the C57BL/6
and APP/PS1+HFD groups than in APP/PS1 group (Figure 5H).
The femoral trabecular bone mass was also evaluated by micro-
CT (Figures 6A–H). We found that the vBMD, tBMD, and
trabecular thickness (Tb.Th) were the same in APP/PS1 mice
and C57BL/6 mice, but these parameters were all significantly
increased by the HFD feeding (Figures 6A,B,F,H). The trabecular
separation (Tb.Sp) was similar in the APP/PS1 mice compared
with the C57BL/6 mice but was reduced in mice on the HFD
(Figure 6G). No significant differences in the BMC and trabecu-
lar number (Tb.N) were found among all groups (Figures 6C,E).
The bone volume fraction (BV/TV) was lower in APP/PS1 mice
than in the C57BL/6 mice and was corrected by the HFD feeding
(Figure 6D).
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FIGURE 4 | HFD ameliorated impairments of femoral mechanical
properties in APP/PS1 mice. In the three-point bending test, the elastic
force (A), ultimate force (B), second moment of inertia (C), elastic stress (D),
and energy (E) were all significantly reduced in APP/PS1 mice compared to
the age-matched C57BL/6 mice. No difference was found in elastic modulus
(F) and stiffness (G) between C57BL/6 and APP/PS1 mice, but HFD
significantly increased these two parameters. Ultimate stress did not vary
among the three groups (H). Femur length was shorter in APP/PS1 mice but
not reversed by HFD (I). Data were means±SEM. n=10 for C57BL/6 mice,
n=12 for APP/PS1 mice, and n=11 for APP/PS1+HFD mice. The results
were analyzed by one-way ANOVA, followed by Newman–Keuls post hoc
test. *p<0.05; **p<0.01; ***p<0.001.
SERUM ALKALINE PHOSPHATASE, CALCIUM, PHOSPHORUS,
ESTROGEN AND LEPTIN LEVELS
Several bone-remodeling-related markers, including serum ALP,
calcium (Ca2+), phosphorus (P), circulating leptin and estradiol
(Figures 7A–E), were measured in this study. The ALP activ-
ity was much higher in the APP/PS1 mice than in the C57BL/6
mice and this increase was significantly reversed by HFD feeding
(Figure 7A). We found no significant difference in Ca2+ levels
either between APP/PS1 mice and C57BL/6 mice, or between
APP/PS1 mice and APP/PS1+HFD mice, but Ca2+ levels were
elevated in the APP/PS1+HFD group compared with that in the
C57BL/6 group (Figure 7B). The P concentration was higher in
the APP/PS1 mice than in the C57BL/6 group, but this effect was
unchanged by HFD feeding (Figure 7C). We found a lower con-
centration of estrogen in the APP/PS1 mice relative to the C57BL/6
mice, and the low level remained in the HFD-fed mice (Figure 7D).
In contrast, there was a trend toward decreased levels of leptin in
the APP/PS1 mice (p= 0.07) compared with the C57BL/6 mice,
and this parameter was significantly elevated by the HFD feeding
(Figure 7E).

























































Peng et al. High-fat-diet ameliorates AD bone loss
FIGURE 5 | HFD protected femoral cortical bone fromAD-involved
impairments. The bone mineral density [BMD, (A)], bone mineral content
[BMC, (B)], and mean thickness [Cr.Th (C)] were lower in the APP/PS1 mice
compared to the C57BL/6 mice, all of which were reversed by HFD feeding.
No significant decrease was found in total area [Tt.Ar (D)] and cortical area
[Ct.Ar (E)] in the APP/PS1 mice compared to the C57BL/6 mice, whereas,
both of which were elevated by HFD feeding. Marrow area (Ma.Ar) did not
vary among the three groups (F). The ratio of Ct.Ar to Tt.Ar was decreased in
APP/PS1 mice (G), but not reversed by HFD feeding. Micrographs showed
the differences of thickness and inner bone surface among all the groups with
arrows indicating the representative part (H). Data were means±SEM. n=7
for C57BL/6 mice, n=8 for APP/PS1 mice, and n=8 for APP/PS1+HFD
mice. The results were analyzed by one-way ANOVA, followed by
Newman–Keuls post hoc test. *p<0.05; **p<0.01; ***p<0.001.
DISCUSSION
SEVERE BONE LOSS AND IMPAIRED BIOMECHANICAL PROPERTIES OF
THE FEMUR IN FEMALE APP/PS1 TRANSGENIC MICE
In APP/PS1 mice, the amyloid pathology can be observed in mice
as young as 3 months, and the amyloid plaque is widely spread
by middle age (9 to 12 months old) (Garcia-Alloza et al., 2006).
In an earlier study by Yang et al., the measurement of BMD and
microarchitecture parameters of both C57BL/6 mice and APP/PS1
mice was performed at the age of 6, 9, and 12 months, respectively.
They found that, even though the amyloid pathology occurred as
early as 3-month age in APP/PS1 mice, the deviation of BMD and
microarchitecture could not be found until 9 months old. And
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FIGURE 6 | HFD improved microarchitecture of femur trabecular bone in
APP/PS1 mice. The volumetric BMD [vBMD (A)], tissue BMD [tBMD (B)],
and trabecular thickness [Tb.Th (F)] were not significantly altered in C57BL/6
mice and APP/PS1 mice; however, these parameters significantly increased
after HFD. Bone volume fraction [BV/TV (D)] was lower in APP/PS1 mice and
recovered after HFD feeding. No significant differences in BMC (C) or
trabecular number [Tb. N (E)] were found among the three groups. The
trabecular separation [Tb.Sp (G)] was not significantly altered in C57BL/6
mice or APP/PS1 mice, and it was reduced after HFD. Micrographs showed
the microarchitecture of femoral trabecule (H) with arrows indicating the
representative part. Data were means±SEM. n=7 for C57BL/6 mice, n=8
for APP/PS1 mice, and n=8 for APP/PS1+HFD mice. The results were
analyzed by one-way ANOVA, followed by Newman–Keuls post hoc test.
*p<0.05; **p<0.01.
at a later time point (12-month age), the deviation of BMD and
microarchitecture become more obvious between AD and control
mice. Therefore, taking the factors into consideration – amyloid
pathology (as early as 3-month old) and osteoporosis pathology
(at 9-month old), we evaluated the bone remodeling induced by
weight gain during the period from AD pathogenesis to the typi-
cal pathology development, i.e., AD mice were given an HFD at 3
months of age and this lasted for 6 months, and the mice were then
sacrificed at 9 months for all the measurements. By measuring the
bone mechanical properties with the three-point bending test and
measuring the BMD and microarchitecture with the micro-CT
system, severe bone loss was detected in the femoral cortical bone
of the transgenic mouse model of AD, suggesting that bone loss
may be associated with amyloid pathogenesis (Yang et al., 2011;
Xia et al., 2013).
As a result of the bone loss, the biomechanical properties
of the femur were severely impaired in the AD mice compared
with the age-matched C57BL/6 mice (Figure 4). These bone
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FIGURE 7 | Serum biochemical characteristics. The ALP level was
higher in APP/PS1 mice than that in C57BL/6 mice, and it was reversed
after HFD feeding (A). The serum Ca2+ levels in APP/PS1 mice was not
different from that of C57BL/6 or APP/PS1+HFD mice; however, it was
higher in APP/PS1+HFD mice than that in C57BL/6 mice (B). The serum
phosphorus level was higher in APP/PS1 mice than that in C57BL/6 mice,
which was not reversed by HFD feeding (C). APP/PS1 mice had a lower
estrogen level than C57BL/6 mice, which was also not reversed by HFD
feeding (D). The serum leptin level was lower in APP/PS1 mice compared
to C57BL/6 mice (p=0.07), and it was significantly induced after HFD
feeding (E). Data were means±SEM. n=7 for C57BL/6 mice, n=9 for
APP/PS1 mice, and n=8 for APP/PS1+HFD mice. The results were
analyzed by one-way ANOVA, followed by Newman–Keuls post hoc test.
*p<0.05; ***p<0.001.
impairments were consistent with the serum biochemical indexes,
including elevated serum ALP levels and P levels in the trans-
genic mice compared with the C57BL/6 mice (Figure 7). The
results suggest a strong link between AD pathology and femoral
bone impairment. In addition, we did not find the weight loss
in middle-aged female AD mice in this study, because it is sup-
posed to emerge in the later stage of the AD with more severe
bone loss.
Yang et al. (2011) reported that in 9-month-old APP/PS1 mice,
parameters including vBMD, tBMD, BV/TV, Tb.Th, and Tb.Sp
in the proximal metaphysis of the tibiae differed from those in
C57BL/6 mice. In this study, the femoral trabecule of the APP/PS1
mice showed no significant alternations of these parameters com-
pared with the control mice (Figure 6). The differences of bone
mass between tibiae and femoral trabecule in APP/PS1 mice may
be due to the presence of fewer trabecule in the femur than that
in the tibia. This finding is consistent with the observation that
the femur is more resistant to bone loss than tibia (Lelovas et al.,
2008).
MODERATE WEIGHT GAIN INDUCED BY HFD BENEFITS AD-INVOLVED
BONE LOSS WITH NO DETRIMENTS OF EXPLORATION ABILITY AND
SPATIAL LEARNING AND MEMORY
In patients with AD, weight loss and osteoporosis are observed and
become worse with AD progression (White et al., 1996; Cronin-
Stubbs et al., 1997; Tan et al., 2005; Lelovas et al., 2008; Zhou et al.,
2011), and the relative risk of death is positively correlated with
increased weight loss in AD cases (White et al., 1998). In contrast
to the weight loss, extreme obesity is a definite risk factor for many
diseases, such as cardiovascular disease and cancer. A new meta-
analysis revealed that obese people, particularly those who are
extremely obese, tend to die earlier than those of normal weight.
However, the findings also suggest that people who are overweight
(but not obese) may live longer than people with clinically normal
body weight (Flegal et al., 2013; Couzin-Frankel, 2014; Solon-Biet
et al., 2014). A lot of studies reported that osteoporosis is accom-
panied with weight loss and bone mass can be improved by weight
gain (Felson et al., 1993; Tremollieres et al., 1993; Frederich et al.,
1995; Considine et al., 1996; Ravn et al., 1999; Lin et al., 2000; De
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Laet et al., 2005; Sheu and Cauley, 2011; Greco et al., 2013; Johans-
son et al., 2014). As expected in this study, the lower values of BMD
and mechanical properties of the femur in transgenic mice were
greatly improved by weight gain.
Notably, the benefit of HFD on bone health is specific for
AD mice but not for normal C57 mice. In a previous study by
Ionova-Martin et al. (2011), 15-week-old C57BL/6 mice received
16-week duration of HFD. Ultimate stress and ultimate force were
15% and 22% less in HFD-fed C57BL/6 mice compared with
those in normal diet-fed C57BL/6 mice, respectively, while BMD,
length, diameter, elastic modulus, and yield stress of their femora
were comparable with those in normal diet-fed C57BL/6 mice.
In another report by Shen et al. (2013), 3-month-old rats were
given an 8-month duration of HFD. They found that HFD feeding
increased bone formation and erosion rates, and decreased trabec-
ular thickness at the tibia. BMD, Tb.N, and Tb.Th of femur in these
HFD-fed rats were comparable with those in normal diet-fed rats.
These studies clearly demonstrated that HFD feeding slightly influ-
enced the mechanical properties and microarchitecture of bone in
rodents.
The femoral bone benefits were fully demonstrated in this
study; however, there is particular concern that body weight gain is
generally linked to cognitive detriments. In this study, we avoided
the extreme HFD (60% calorie from fat) feeding, which is known
to lead to severe obesity, brain insulin resistance, and spatial mem-
ory impairment both in AD mouse model and normal C57BL/6
mouse (Ho et al., 2004; Moroz et al., 2008; Barron et al., 2013;
Leboucher et al., 2013). Instead, we employed a 6-month feeding
regimen of a 45% fat diet which resulted in a body weight gain
in the transgenic mouse model of AD. The 6-month HFD feed-
ing was implemented in 3-month-old APP/PS1 mice. Body weight
at 5, 7, and 9 months (the end of the feeding) of HFD-fed mice
were 17.9, 60.1, and 68.8% higher than the age-matched APP/PS1
mice fed with the normal-fat diet, respectively. These levels of
weight gain are equivalent to a range of overweight to moderate
obesity, but not severe obesity in humans. 45% HFD feeding, as
reported in previous study, caused little impairment in the rodent
central insulin signaling and spatial memory (Mielke et al., 2006;
McNeilly et al., 2012) but a disability in performance of an operant
bar-pressing task (Mielke et al., 2006; McNeilly et al., 2011). We
confirmed that HFD did not exacerbate the exploration ability and
working, learning, and memory performance during the 6 months
of feeding compared to the transgenic mice fed a normal-fat diet
(Figures 2A–D). Furthermore, the brain Aβ processing and brain
insulin signaling, which are considered to be involved in Aβ plaque
deposit and cognition dysfunction (Farooki, 2009), were not sig-
nificantly altered by the HFD feeding (Figures 3A–I). Therefore,
a strategy of moderate body weight gain, such as by the mean
of moderate HFD regimen, should not be precluded, especially
in case of diseases with progressive weight loss such as AD and
AD-involved osteoporosis.
In addition to the effects of diets at different fat levels (10 or 45%
calorie from fat) on spatial working, learning, and memory mea-
surement as in this study, future studies should evaluate whether
longer periods of HFD feeding lead to disability in other aspects
of cognitive performance, such as delayed matching and non-
matching to position task. Additionally, it remains to be defined
whether the fat or the muscle gain is responsible for the bone
improvement during HFD feeding. And other metabolic disorders
will also need to be carefully assessed in future studies.
ELEVATED CIRCULATING LEPTIN INDUCED BY WEIGHT GAIN WAS
INVOLVED IN BONE REMODELING IN FEMALE APP/PS1 MOUSE FED HFD
Both estrogen and leptin exhibit regulatory effects on bone for-
mation and degradation. Leptin can ameliorate OVX-induced
osteoporosis (Burguera et al., 2001). These effects may be due to
peripheral stimulation of osteoblast proliferation and inhibition
of osteoclastogenesis mediated by signaling through osteoprote-
gerin (OPG)/receptor–activator of NF-κB (RANK) and its ligand
(RANKL). However, an indirect action of leptin via estradiol can-
not be excluded (Yasuda et al., 1998; Thomas et al., 1999; Burguera
et al., 2001; Holloway et al., 2002; Martin and Sims, 2005; Wada
et al., 2006; Xue et al., 2012).
In the APP/PS1 mice, we found that the serum estradiol lev-
els were reduced compared with the C57BL/6 mice. HFD feeding
did not alter the circulating level of estradiol in the transgenic
mice (Figure 7D), implying that estrogen level may contribute to
bone loss but is not associated with the body weight gain-induced
improvement of the bone mass in the transgenic mice. This find-
ing is consistent with a report that total estrogen was similar in
both obese and non-obese postmenopausal women (Albala et al.,
1996).
Previous reports have well addressed the role of leptin in the
regulation of bone health showing that the administration of lep-
tin leads to an increase in the BMD in mice (Burguera et al., 2001;
Sienkiewicz et al., 2011). In the AD brain, there are higher levels of
leptin but lower levels of leptin receptor mRNA, thus suggesting
that the AD brain exhibits impaired brain leptin signaling, namely
less leptin receptor, as well as less interaction between the leptin
and leptin receptors (Lieb et al., 2009; Zhou et al., 2011; Bonda
et al., 2013). The enhanced bone mass induced by weight gain in
female APP/PS1 mice might therefore be attributed to the periph-
eral action of leptin rather than brain leptin signaling (Burguera
et al., 2001), through peripheral stimulation of osteoblast prolifer-
ation and inhibition of osteoclastogenesis (Holloway et al., 2002;
Martin and Sims, 2005). In contrast to the HFD-induced benefi-
cial effect to the bone quality in AD mice, a higher level of leptin
induced by HFD in adult C57BL/6 mice did not lead to enhanced
bone mechanical properties (Ionova-Martin et al., 2011), which
suggests that leptin acts differently in osteoporosis-involved AD
mice than it does in normal controls fed with HFD. Here, in this
study, we still lack solid evidence linking leptin to bone quality in
AD mice. Therefore, the underlying mechanism of leptin in regu-
lating osteoblast proliferation and osteoclastogenesis still needs to
be elucidated in female patient with AD.
Taken together, the body weight gain induced by the HFD feed-
ing regimen completely improved the AD-involved femoral bone
loss without adverse effects on the exploration ability and spa-
tial memory impairment in the APP/PS1 transgenic mouse model
of AD. Patients with AD always develop both progressive weight
loss and osteoporosis. Our findings suggest that HFD may be an
effective dietary administration for progressive weight loss and
osteoporosis in patients with AD without a substantial impact on
cognitive function. Further research is required to optimize the
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composition of the HFD in order to minimize the possible nega-
tive effect induced by HFD, for instance, the risk of cardiovascular
disease and cognition impairment.
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